Symbols / BLTE
BLTE Chart
About
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 6.98B |
| Enterprise Value | 6.33B | Income | -62.39M | Sales | — |
| Book/sh | 7.86 | Cash/sh | 7.90 | Dividend Yield | — |
| Payout | 0.00% | Employees | 25 | IPO | — |
| P/E | — | Forward P/E | -155.50 | PEG | — |
| P/S | — | P/B | 23.70 | P/C | — |
| EV/EBITDA | -93.89 | EV/Sales | — | Quick Ratio | 34.17 |
| Current Ratio | 34.37 | Debt/Eq | 0.19 | LT Debt/Eq | — |
| EPS (ttm) | -1.92 | EPS next Y | -1.20 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-02 | ROA | -21.22% |
| ROE | -32.30% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 37.51M |
| Shs Float | 15.75M | Short Float | 2.93% | Short Ratio | 2.42 |
| Short Interest | — | 52W High | 200.00 | 52W Low | 49.00 |
| Beta | -1.46 | Avg Volume | 251.48K | Volume | 115.38K |
| Target Price | $195.75 | Recom | Strong_buy | Prev Close | $189.26 |
| Price | $186.15 | Change | -1.64% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$195.75
Mean price target
2. Current target
$186.15
Latest analyst target
3. DCF / Fair value
$49.64
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$186.15
Low
$185.00
High
$223.00
Mean
$195.75
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-28 | reit | HC Wainwright & Co. | Buy → Buy | $185 |
| 2026-01-26 | init | B of A Securities | — → Buy | $195 |
| 2026-01-06 | init | Morgan Stanley | — → Overweight | $191 |
| 2025-12-02 | up | Mizuho | Neutral → Outperform | $194 |
| 2025-12-01 | main | HC Wainwright & Co. | Buy → Buy | $185 |
| 2025-11-20 | init | Mizuho | — → Neutral | $105 |
| 2025-10-31 | main | Benchmark | Buy → Buy | $132 |
| 2025-09-15 | main | HC Wainwright & Co. | Buy → Buy | $98 |
| 2025-07-03 | reit | HC Wainwright & Co. | Buy → Buy | $100 |
| 2025-05-15 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
| 2025-05-15 | reit | HC Wainwright & Co. | Buy → Buy | $100 |
| 2025-03-26 | reit | Benchmark | Buy → Buy | $80 |
| 2025-03-18 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
| 2025-03-18 | reit | HC Wainwright & Co. | Buy → Buy | $100 |
| 2025-01-21 | main | Benchmark | Buy → Buy | $79 |
| 2024-11-15 | main | Maxim Group | Buy → Buy | $110 |
| 2024-11-13 | main | HC Wainwright & Co. | Buy → Buy | $100 |
| 2024-09-12 | reit | HC Wainwright & Co. | Buy → Buy | $60 |
| 2024-08-13 | main | HC Wainwright & Co. | Buy → Buy | $60 |
| 2024-08-13 | reit | Benchmark | Buy → Buy | $57 |
- Assessing Belite Bio (BLTE) Valuation As Price To Book And DCF Send Mixed Signals - Yahoo Finance ue, 24 Feb 2026 17
- Liquidity Mapping Around (BLTE) Price Events - Stock Traders Daily Mon, 23 Feb 2026 14
- Belite Bio, Inc (BLTE) Stock Report: Analyst Ratings Signal Strong Buy with 9.62% Potential Upside - DirectorsTalk Interviews ue, 17 Feb 2026 15
- Belite Bio Stock (BLTE) Opinions on Phase 3 DRAGON Trial Results - Quiver Quantitative ue, 02 Dec 2025 08
- Belite Bio (NASDAQ: BLTE) prices $350M ADS offer to back commercialization, pipeline - Stock Titan Mon, 01 Dec 2025 08
- Belite Bio On A Tear As It Approaches Key Regulatory Submissions (NASDAQ:BLTE) - Seeking Alpha ue, 27 Jan 2026 08
- Belite Bio (BLTE) Valuation Check After Completing Enrollment In Pivotal DRAGON II Trial - simplywall.st Mon, 09 Feb 2026 08
- Belite Bio stock soars after breakthrough Phase 3 results for Stargardt disease - Investing.com Mon, 01 Dec 2025 08
- BLTE: HC Wainwright & Co. Reiterates Buy Rating with $185 Target - GuruFocus Wed, 28 Jan 2026 10
- Belite Bio, Inc (BLTE) Stock Analysis: Biotechnology Innovator With 4.98% Potential Upside - DirectorsTalk Interviews ue, 10 Feb 2026 08
- Mizuho Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $223 - 富途牛牛 hu, 19 Feb 2026 22
- The $100 Club - Were You Early To The Triple-Digit Rally In ABVX, NUTX, BLTE…? - Nasdaq Fri, 19 Dec 2025 08
- Belite Bio (NASDAQ: BLTE) begins ADS sale to support pipeline and commercialization - Stock Titan Mon, 01 Dec 2025 08
- Belite Bio (BLTE): Is the Biotech's High Valuation Justified After Its Recent Share Price Surge? - Yahoo Finance hu, 30 Oct 2025 07
- Why (BLTE) Price Action Is Critical for Tactical Trading - Stock Traders Daily hu, 12 Feb 2026 12
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.00 | 0.00 |
| NormalizedEBITDA | -35.67M | -31.20M | -12.43M | -9.64M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -36.14M | -31.63M | -12.65M | -9.67M |
| ReconciledDepreciation | 449.00K | 399.00K | 198.00K | 30.00K |
| EBITDA | -35.67M | -31.20M | -12.43M | -9.64M |
| EBIT | -36.12M | -31.60M | -12.63M | -9.67M |
| NetInterestIncome | 3.72M | 49.00K | 7.00K | 5.00K |
| InterestExpense | 20.00K | 25.00K | 16.00K | 0.00 |
| InterestIncome | 3.74M | 74.00K | 23.00K | 5.00K |
| NormalizedIncome | -36.14M | -31.63M | -12.65M | -9.67M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -36.14M | -31.63M | -12.65M | -9.67M |
| TotalExpenses | 40.00M | 31.67M | 12.82M | 9.80M |
| TotalOperatingIncomeAsReported | -40.00M | -31.67M | -12.82M | -9.80M |
| DilutedAverageShares | 30.54M | 26.59M | 19.98M | 24.10M |
| BasicAverageShares | 30.54M | 26.59M | 19.98M | 24.10M |
| DilutedEPS | -1.18 | -1.19 | -0.63 | -0.40 |
| BasicEPS | -1.18 | -1.19 | -0.63 | -0.40 |
| DilutedNIAvailtoComStockholders | -36.14M | -31.63M | -12.65M | -9.67M |
| NetIncomeCommonStockholders | -36.14M | -31.63M | -12.65M | -9.67M |
| NetIncome | -36.14M | -31.63M | -12.65M | -9.67M |
| NetIncomeIncludingNoncontrollingInterests | -36.14M | -31.63M | -12.65M | -9.67M |
| NetIncomeContinuousOperations | -36.14M | -31.63M | -12.65M | -9.67M |
| TaxProvision | 6.00K | 9.00K | 0.00 | 0.00 |
| PretaxIncome | -36.14M | -31.62M | -12.65M | -9.67M |
| OtherIncomeExpense | 141.00K | -4.00K | 166.00K | 126.00K |
| OtherNonOperatingIncomeExpenses | 141.00K | -4.00K | 166.00K | 126.00K |
| NetNonOperatingInterestIncomeExpense | 3.72M | 49.00K | 7.00K | 5.00K |
| InterestExpenseNonOperating | 20.00K | 25.00K | 16.00K | 0.00 |
| InterestIncomeNonOperating | 3.74M | 74.00K | 23.00K | 5.00K |
| OperatingIncome | -40.00M | -31.67M | -12.82M | -9.80M |
| OperatingExpense | 40.00M | 31.67M | 12.82M | 9.80M |
| ResearchAndDevelopment | 29.94M | 24.84M | 8.87M | 7.42M |
| SellingGeneralAndAdministration | 10.06M | 6.82M | 3.95M | 2.38M |
| GeneralAndAdministrativeExpense | 10.06M | 6.82M | 3.95M | 2.38M |
| OtherGandA | 10.06M | 6.82M | 3.95M | 2.38M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | ||
|---|---|---|---|---|
| TreasurySharesNumber | 31.25K | 35.03K | ||
| OrdinarySharesNumber | 31.83M | 29.15M | 24.90M | 24.10M |
| ShareIssued | 31.86M | 29.18M | 24.90M | 24.10M |
| TotalDebt | 537.00K | 886.00K | 866.00K | 0.00 |
| TangibleBookValue | 141.83M | 87.13M | 41.47M | -15.09M |
| InvestedCapital | 145.82M | 90.43M | 41.50M | -15.09M |
| WorkingCapital | 141.02M | 86.31M | 40.70M | 15.80M |
| NetTangibleAssets | 141.83M | 87.13M | 41.47M | -15.09M |
| CapitalLeaseObligations | 537.00K | 886.00K | 866.00K | 0.00 |
| CommonStockEquity | 145.82M | 90.43M | 41.50M | -15.09M |
| TotalCapitalization | 145.82M | 90.43M | 41.50M | -15.09M |
| TotalEquityGrossMinorityInterest | 145.82M | 90.43M | 41.50M | -15.09M |
| StockholdersEquity | 145.82M | 90.43M | 41.50M | -15.09M |
| GainsLossesNotAffectingRetainedEarnings | -660.00K | -374.00K | -392.00K | -196.00K |
| RetainedEarnings | -107.65M | -71.50M | -39.87M | -27.22M |
| AdditionalPaidInCapital | 254.12M | 162.31M | 81.76M | 12.32M |
| CapitalStock | 3.00K | 3.00K | 3.00K | 1.00K |
| CommonStock | 3.00K | 3.00K | 3.00K | 1.00K |
| TotalLiabilitiesNetMinorityInterest | 6.31M | 4.21M | 2.77M | 33.44M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 261.00K | 578.00K | 668.00K | 31.81M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 31.81M | ||
| LongTermDebtAndCapitalLeaseObligation | 261.00K | 578.00K | 668.00K | 0.00 |
| LongTermCapitalLeaseObligation | 261.00K | 578.00K | 668.00K | 0.00 |
| CurrentLiabilities | 6.05M | 3.63M | 2.10M | 1.64M |
| OtherCurrentLiabilities | 289.00K | 149.00K | 74.00K | 95.00K |
| CurrentDebtAndCapitalLeaseObligation | 276.00K | 308.00K | 198.00K | |
| CurrentCapitalLeaseObligation | 276.00K | 308.00K | 198.00K | 0.00 |
| PensionandOtherPostRetirementBenefitPlansCurrent | 703.00K | 727.00K | 382.00K | 56.00K |
| PayablesAndAccruedExpenses | 4.78M | 2.45M | 1.45M | 1.48M |
| CurrentAccruedExpenses | 4.77M | 2.45M | 1.45M | 1.41M |
| Payables | 13.00K | 71.00K | ||
| DuetoRelatedPartiesCurrent | 13.00K | 0.00 | 0.00 | 71.00K |
| TotalAssets | 152.13M | 94.64M | 44.27M | 18.35M |
| TotalNonCurrentAssets | 5.06M | 4.70M | 1.47M | 917.00K |
| OtherNonCurrentAssets | 62.00K | |||
| NonCurrentPrepaidAssets | 103.00K | 104.00K | 88.00K | 8.00K |
| NonCurrentDeferredAssets | 0.00 | 815.00K | ||
| GoodwillAndOtherIntangibleAssets | 3.99M | 3.30M | 31.00K | |
| OtherIntangibleAssets | 3.99M | 3.30M | 31.00K | |
| NetPPE | 965.00K | 1.30M | 1.35M | 94.00K |
| AccumulatedDepreciation | -341.00K | -183.00K | -91.00K | -47.00K |
| GrossPPE | 1.31M | 1.48M | 1.44M | 141.00K |
| Leases | 187.00K | 187.00K | 187.00K | 0.00 |
| ConstructionInProgress | 31.00K | 0.00 | ||
| OtherProperties | 1.04M | 1.23M | 1.23M | 141.00K |
| MachineryFurnitureEquipment | 75.00K | 64.00K | 23.00K | 0.00 |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 147.07M | 89.94M | 42.81M | 17.43M |
| PrepaidAssets | 1.33M | 916.00K | 699.00K | 64.00K |
| Receivables | 594.00K | 867.00K | 19.00K | 23.00K |
| OtherReceivables | 818.00K | |||
| DuefromRelatedPartiesCurrent | 0.00 | 18.00K | 2.00K | 0.00 |
| TaxesReceivable | 19.00K | 31.00K | 17.00K | 23.00K |
| AccruedInterestReceivable | 575.00K | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 145.15M | 88.16M | 42.09M | 17.34M |
| OtherShortTermInvestments | 113.47M | 0.00 | ||
| CashAndCashEquivalents | 31.68M | 88.16M | 42.09M | 17.34M |
| CashFinancial | 31.68M | 88.16M | 42.09M | 17.34M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -29.39M | -29.90M | -11.85M | -7.55M |
| RepaymentOfDebt | 0.00 | 0.00 | ||
| IssuanceOfDebt | 0.00 | 0.00 | ||
| IssuanceOfCapitalStock | 42.24M | 55.19M | 37.99M | 0.00 |
| CapitalExpenditure | -151.00K | -63.00K | -394.00K | -74.00K |
| InterestPaidSupplementalData | 0.00 | 0.00 | 16.00K | 0.00 |
| IncomeTaxPaidSupplementalData | 6.00K | 9.00K | 0.00 | 0.00 |
| EndCashPosition | 31.68M | 88.16M | 42.09M | 17.34M |
| BeginningCashPosition | 88.16M | 42.09M | 17.34M | 25.62M |
| EffectOfExchangeRateChanges | -269.00K | 9.00K | -366.00K | -161.00K |
| ChangesInCash | -56.21M | 46.06M | 25.11M | -8.11M |
| FinancingCashFlow | 83.59M | 75.96M | 36.96M | -583.00K |
| CashFlowFromContinuingFinancingActivities | 83.59M | 75.96M | 36.96M | -583.00K |
| NetOtherFinancingCharges | -368.00K | -1.23M | -1.03M | -815.00K |
| ProceedsFromStockOptionExercised | 41.73M | 22.00M | 3.00K | 232.00K |
| NetPreferredStockIssuance | 0.00 | 0.00 | ||
| PreferredStockIssuance | 0.00 | 0.00 | ||
| NetCommonStockIssuance | 42.24M | 55.19M | 37.99M | 0.00 |
| CommonStockIssuance | 42.24M | 55.19M | 37.99M | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | ||
| NetLongTermDebtIssuance | 0.00 | 0.00 | ||
| LongTermDebtPayments | 0.00 | 0.00 | ||
| LongTermDebtIssuance | 0.00 | 0.00 | ||
| InvestingCashFlow | -110.57M | -63.00K | -394.00K | -56.00K |
| CashFlowFromContinuingInvestingActivities | -110.57M | -63.00K | -394.00K | -56.00K |
| NetInvestmentPurchaseAndSale | -110.42M | 0.00 | 0.00 | |
| SaleOfInvestment | 77.84M | 0.00 | 0.00 | |
| PurchaseOfInvestment | -188.26M | 0.00 | 0.00 | |
| NetIntangiblesPurchaseAndSale | -35.00K | 0.00 | 0.00 | |
| PurchaseOfIntangibles | -35.00K | 0.00 | 0.00 | |
| NetPPEPurchaseAndSale | -116.00K | -63.00K | -394.00K | -56.00K |
| SaleOfPPE | 0.00 | 0.00 | 18.00K | |
| PurchaseOfPPE | -116.00K | -63.00K | -394.00K | -74.00K |
| OperatingCashFlow | -29.23M | -29.84M | -11.46M | -7.47M |
| CashFlowFromContinuingOperatingActivities | -29.23M | -29.84M | -11.46M | -7.47M |
| ChangeInWorkingCapital | 1.13M | -2.43M | -491.00K | 640.00K |
| ChangeInOtherCurrentLiabilities | -305.00K | -244.00K | -71.00K | 0.00 |
| ChangeInPayablesAndAccruedExpense | 2.48M | 1.42M | 332.00K | 677.00K |
| ChangeInAccruedExpense | 2.46M | 1.42M | 373.00K | 632.00K |
| ChangeInPayable | 13.00K | -41.00K | 45.00K | |
| ChangeInPrepaidAssets | -1.11M | -3.53M | -720.00K | -37.00K |
| ChangeInReceivables | 74.00K | -72.00K | -32.00K | 0.00 |
| OtherNonCashItems | -3.61M | |||
| StockBasedCompensation | 8.99M | 3.82M | 1.48M | 1.53M |
| UnrealizedGainLossOnInvestmentSecurities | -49.00K | 0.00 | 0.00 | |
| DepreciationAmortizationDepletion | 449.00K | 399.00K | 198.00K | 30.00K |
| DepreciationAndAmortization | 449.00K | 399.00K | 198.00K | 30.00K |
| AmortizationCashFlow | 4.00K | 0.00 | 0.00 | |
| AmortizationOfIntangibles | 4.00K | 0.00 | 0.00 | |
| Depreciation | 445.00K | 399.00K | 198.00K | 30.00K |
| OperatingGainsLosses | -8.00K | |||
| GainLossOnSaleOfPPE | 0.00 | 0.00 | -8.00K | |
| NetIncomeFromContinuingOperations | -36.14M | -31.63M | -12.65M | -9.67M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for BLTE
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|